Analysis of the Correlation between CD3<sup>-/dim</sup>CD4<sup>+</sup> Mature Lymphocytes in Bone Marrow and Peripheral T-cell Lymphoma

doi:10.13523/j.cb.2310058

China Biotechnology

2023, Vol. 43

Issue (12): 53-59 DOI: 10.13523/j.cb.2310058

Analysis of the Correlation between CD3^-/dimCD4⁺ Mature Lymphocytes in Bone Marrow and Peripheral T-cell Lymphoma

ZHANG Mu-yang,LIAO Hong-yan,JIN Yong-mei,JIANG Neng-gang(

)

Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu 610041, China

Download:

HTML

PDF(1153KB) HTML
Export: BibTeX | EndNote (RIS)

Abstract

Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of lymphomas derived from neoplastic transformation of mature T lymphocytes. The value of CD3^-/dimCD4⁺ abnormal cell population detected in the bone marrow and peripheral blood is unclear in the diagnosis of PTCL. In this study, 67 patients with CD3^-/dimCD4⁺ abnormal T-cell populations were grouped according to the final pathological and clinical diagnosis. The patients' data including peripheral blood count, biochemistry indices, immunoglobulin, inflammatory factors, and residual normal T-cell subpopulations were used to explore whether this abnormal lymphocyte population is significant for the identification of various types of PTCL. The results indicate that CD3^-/dimCD4⁺ cells found in the bone marrow are associated with T cell disorders, and the angioimmunoblastic T-cell lymphoma (AITL) is the most common type of PTCL. However, the immunophenotyping and laboratory indices of different PTCL groups overlap each other, which should be carefully differentially diagnosed by combining the clinical features and pathological results.

Key words： Peripheral T-cell lymphoma (PTCL) CD3 CD4 Flow cytometry

Received: 14 October 2023 Published: 16 January 2024

ZTFLH:

Q46Q354

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Mu-yang ZHANG
	Hong-yan LIAO
	Yong-mei JIN
	Neng-gang JIANG

Cite this article:

Mu-yang ZHANG, Hong-yan LIAO, Yong-mei JIN, Neng-gang JIANG. Analysis of the Correlation between CD3^-/dimCD4⁺ Mature Lymphocytes in Bone Marrow and Peripheral T-cell Lymphoma. China Biotechnology, 2023, 43(12): 53-59.

URL:

https://manu60.magtech.com.cn/biotech/10.13523/j.cb.2310058 OR https://manu60.magtech.com.cn/biotech/Y2023/V43/I12/53

Table 1 General clinical characteristics of the patients

Fig.1 Abnormal immunophenotyping of T-lymphocytes Red population with strong expression of CD4, CD5, and CD45

Table 2 Flow cytometry immunophenotyping of CD3^-/dimCD4⁺ T lymphocytes

Fig.2 Correlation of the proportion of CD3^-/dimCD4⁺ abnormal cells in bone marrow and peripheral blood samples of the same patients (n=9)(P>0.05)

项目	AITL(n=46)	FTCL(n=6)	MF(n=5)	L-HES(n=7)	T-PLL(n=3)	P
RBC(×10¹²/L)	4.10 (2.28~5.58)	3.87 (2.98~5.53)	4.51 (2.63~4.99)	4.38 (3.70~7.16)	3.19 (2.05~4.54)	0.492
WBC(×10⁹/L)	6.96 (1.91~44.87)	6.73 (3.05~14.85)	7.63 (2.07~13.61)	14.24 (9.54~20.57)	131.4 (85.28~180.3)	0.003
Nsg/%	70.05 (29.00~85.00)	59.95 (28.0~77.40)	53.00 (30.20~68.10)	28.20 (15.50~58.90)	5.00 (4.00~9.00)	0.000
Nsg(×10⁹/L)	4.99 (1.38~32.31)	2.92 (1.59~11.27)	2.40 (1.41~5.72)	3.19 (2.87~9.54)	6.57 (3.41~16.23)	0.248
L/%	14.55 (2.00~42.90)	26.15 (11.20~50.00)	28.00 (21.00~60.20)	16.40 (3.10~27.30)	90.00 (89.00~90.00)	0.002
L(×10⁹/L)	1.04 (0.25~6.13)	1.80 (0.79~3.40)	2.14 (0.47~8.19)	2.34 (0.39~5.62)	118.3 (81.02~160.5)	0.010
M/%	8.25 (0.80~21.00)	8.85 (5.00~10.70)	9.20 (5.00~12.10)	2.85 (2.10~7.10)	2.00 (1.00~5.00)	0.001
M(×10⁹/L)	0.58 (0.040~1.73)	0.51 (0.31~0.80)	0.92 (0.17~1.03)	0.40 (0.28~1.34)	3.61 (0.85~6.57)	0.157
E/%	1.80 (0~25.00)	2.00 (0.30~16.40)	9.70 (0~11.40)	48.05 (19.60~69.40)	-	0.001
E(×10⁹/L)	0.13 (0~7.63)	0.12 (0.02~1.09)	0.37 (0~1.16)	5.56 (3.74~12.85)	-	0.001
B/%	0.50 (0.10~5.58)	0.40 (0.30~0.70)	1.00 (0~2.40)	0.40 (0.20~1.10)	-	0.611
B(×10⁹/L)	0.030 (0.10~0.59)	0.020 (0.020~0.040)	0.070 (0~0.25)	0.055 (0.040~0.17)	-	0.118
PCT/(ng/mL)	0.23 (0.020~2.22)	0.040 (0.020~0.080)	3.19 (0.21~6.17)	0.060 (0.020~1.20)	-	0.099
LDH/(U/L)	262.5 (84.0~682.0)	235.0 (170.0~570.0)	228.0 (129.0~338.0)	235.0 (140.0~597.0)	401.0 (207.0~708.0)	0.674
CRP/(mg/L)	20.35 (1.00~164.0)	23.47 (1.25~39.90)	29.30 (2.04~71.20)	6.51 (1.25~67.40)	3.45 (2.32~4.58)	0.472
IL-6/(pg/mL)	17.65 (1.50~269.0)	4.61 (2.50~16.40)	17.51 (6.61~28.40)	2.22 (1.50~46.80)	-	0.166
IgG/(g/L)	11.20 (5.94~34.60)	12.75 (10.40~52.20)	-	6.31 (4.45~9.59)	-	0.054
IgA/(mg/L)	1760 (729~6 850)	1 945 (1 360~4 130)	-	1330 (366.0~1820)	-	0.560
IgM/(mg/L)	892 (295~18 300)	1 185 (625~3 840)	-	855(431~2910)	-	0.892
CD3⁺CD4⁺/CD3⁺	0.36 (0.13~0.70)	0.34 (0.22~0.53)	0.45 (0.28~0.89)	0.39 (0.21~0.62)	0.45 (0.41~0.50)	0.622
CD3⁺CD8⁺/CD3⁺	0.56 (0.24~0.81)	0.59 (0.40~0.71)	0.28 (0.058~0.71)	0.58(0.28~0.72)	0.50(0.43~0.52)	0.577
异常CD3^-/dim CD4⁺ / 成熟淋巴细胞	0.027 (0.000 7~0.76)	0.029 (0.001~0.18)	0.016 (0.002 0~0.83)	0.030 (0.010~0.66)	0.81 (0.67~1.00)	0.067
骨髓浆细胞/%	1.00 (0 ~7.50)	1.00 (0~5.00)	0.00 (0~1.00)	0.50 (0~1.00)	0.50 (0~0.50)	0.012

Table 3 Comparison of laboratory indices among five groups

Fig.3 Comparison of laboratory indices among five groups


[1]	Bruneau J, Molina T J. WHO classification of tumors of hematopoietic and lymphoid tissues //Van Krieken J H J M. Encyclopedia of pathology. Cham:Springer International Publishing, 2019: 1-5.

[2]	Wang H P, Holst J, Woo S R, et al. Tonic ubiquitylation controls T-cell receptor: CD 3 complex expression during T-cell development. The EMBO Journal, 2010, 29(7): 1285-1298. doi: 10.1038/emboj.2010.10

[3]	Tembhare P R, Chatterjee G, Chaturvedi A, et al. Critical role of flow cytometric immunophenotyping in the diagnosis, subtyping, and staging of T-cell/NK-cell non-Hodgkin’s lymphoma in real-world practice: a study of 232 cases from a tertiary cancer center in India. Frontiers in Oncology, 2022, 12: 779230. doi: 10.3389/fonc.2022.779230

[4]	Alikhan M, Song J Y, Sohani A R, et al. Peripheral T-cell lymphomas of follicular helper T-cell type frequently display an aberrant CD3-/dimCD4+ population by flow cytometry: an important clue to the diagnosis of a Hodgkin lymphoma mimic. Modern Pathology, 2016, 29(10): 1173-1182. doi: 10.1038/modpathol.2016.113 pmid: 27312067

[5]	Singh A, Schabath R, Ratei R, et al. Peripheral blood sCD3- CD4+ T cells: a useful diagnostic tool in angioimmunoblastic T cell lymphoma. Hematological Oncology, 2014, 32(1): 16-21. doi: 10.1002/hon.2080 pmid: 23798351

[6]	李爱平, 石旦, 李晓杰. 血管免疫母细胞性T细胞淋巴瘤的特征和诊治进展. 中南医学科学杂志, 2020, 48(3):320-322, 326.

[6]	Li A P, Shi D, Li X J. The progress in the characteristics, diagnosis and treatment of angioimmunoblastic T-cell lymphoma. Medical Science Journal of Central South China, 2020, 48(3):320-322, 326.

[7]	Rüdiger T, Ichinohasama R, Ott M M, et al. Peripheral T-cell lymphoma with distinct perifollicular growth pattern. The American Journal of Surgical Pathology, 2000, 24(1): 117-122. doi: 10.1097/00000478-200001000-00014

[8]	Roufosse F, Cogan E, Goldman M. Lymphocytic variant hypereosinophilic syndromes. Immunology and Allergy Clinics of North America, 2007, 27(3): 389-413. pmid: 17868856

[9]	Carpentier C, Verbanck S, Schandené L, et al. Eosinophilia associated with CD3-CD4+ T cells: characterization and outcome of a single-center cohort of 26 patients. Frontiers in Immunology, 2020, 11: 1765. doi: 10.3389/fimmu.2020.01765 pmid: 32849632

[10]	Horna P, Wang S A, Wolniak K L, et al. Flow cytometric evaluation of peripheral blood for suspected Sézary syndrome or mycosis fungoides: international guidelines for assay characteristics. Cytometry Part B: Clinical Cytometry, 2021, 100(2): 142-155. doi: 10.1002/cyto.b.v100.2

[11]	李鑫静, 陈宝珍, 陈燕坪, 等. 系统性间变性大细胞淋巴瘤的免疫组织化学特征. 临床与病理杂志, 2017, 37(5):970-974.

[11]	Li X J, Chen B Z, Chen Y P, et al. Immunohistochemical features of systemic anaplastic large cell lymphoma. International Journal of Pathology and Clinical Medicine, 2017, 37(5):970-974.

[1]	Chun-yan WANG, Song-ya LIU, Li ZHU, Shu-juan YI, Dong KUANG, Ming XIAO, Xia MAO. Immunophenotypic Characterization of Nodal Follicular Helper T Cell Lymphoma, Angioimmunoblastic-type[J]. China Biotechnology, 2023, 43(12): 39-45.

[2]	Nian-gui CAI, Xin CHEN, Qing-yuan ZHANG, Hao-nan DI, Xiao-zhen ZHAN, Jun-yan CHEN, Hao CHEN, Xiao-mei YAN. Exploring the Nanoworld: Development and Single-Particle-Level Characterization of Nano-flow Cytometry Technology[J]. China Biotechnology, 2023, 43(12): 1-13.

[3]	Wei-hua SHI, Yan-rong LIU, Yan CHANG, Xiao-ying YUAN, Ling-ling HE, Le HAO, Jia-yi YIN, Jing-quan LU, Ya-zhe WANG. TRBC1 and TCR Vβ Comparative Analysis of Two Flow Cytometry Methods for Detecting T Cell Clonality[J]. China Biotechnology, 2023, 43(12): 102-110.

[4]	Yue-meng LIU, Si-han DONG, Xun-bin WEI. *Advances in the Study and Application of in vivo* Flow Cytometry**[J]. China Biotechnology, 2023, 43(12): 14-23.

[5]	Xiao-xue XU, Shi-yu TIAN, Hao-jie WEI, Nai-li HU, Lin-yue ZOU, Lu KONG. Quantification of Surface Protein Molecules in Human Lymphocyte Subsets[J]. China Biotechnology, 2023, 43(12): 153-159.

[6]	Zhi-hong YANG, Ya-qi ZHANG, Yong-ze BAI, Xiu-ying TANG, Yu-ying ZHANG, Xia LI. The Clinical Application Value of Immunophenotype Analysis by Flow Cytometry in the Diagnosis and Treatment of Multiple Myeloma[J]. China Biotechnology, 2023, 43(12): 78-85.

[7]	YANG Xiao-ying,LI Meng,ZHAO Wei,TANG Min,ZHANG Zhi-qian. Preparation and Preliminary Characterization of Anti-α2δ1/CD3 Bispecific Antibody[J]. China Biotechnology, 2020, 40(7): 9-14.

[8]	HE Ling-ling,LUO Ting-ting,CHANG Yan,WANG Ya-zhe,YUAN Xiao-ying,SHI Wei-hua,LAI Yue-yun,SHI Hong-xia,QIN Ya-zhen,HUANG Xiao-jun,LIU Yan-rong. Analysis on the Laboratory Examination Characteristics in 28 Patients with Acute Megakaryoblastic Leukemia[J]. China Biotechnology, 2019, 39(9): 2-10.

[9]	ZHAO Si-shu,LIU Lu,LIU Fang,QIU Hai-rong,FAN Lei,LI Jian-yong,WU Yu-jie. Diagnostic Value of CD11c Antigen in Patients with Chronic Lymphocytic Leukemia[J]. China Biotechnology, 2019, 39(9): 19-24.

[10]	YUAN Xiao-ying,WANG Ya-zhe,SHI Wei-hua,CHANG Yan,HAO Le,HE Ling-ling,SHI Hong-xia,HUANG Xiao-jun,LIU Yan-rong. Methodological Study on Flow Detection of PNH Clone and Its Clinical Screening Significance[J]. China Biotechnology, 2019, 39(9): 33-40.

[11]	HUI Yi-hua,WANG Hai-na,QI Yu-feng,CAO Xue-ling,GUAN Xue-mei,DUAN Jing-jing,DUAN Yi- jun,WANG Yan- feng,SU Wen. Normal Reference Range of Lymphocyte Subsets in Healthy Adults in Shanxi Province[J]. China Biotechnology, 2019, 39(9): 41-49.

[12]	Hang Hai-ying,Liu Chun-chun,Ren Dan-dan. Development, Application and Prospection of Flow Cytometry[J]. China Biotechnology, 2019, 39(9): 68-83.

[13]	PENG Xian-gui,YANG Wu-chen,LI Jia,GOU Yang,WANG Ping,LIU Si-heng,ZHANG Yun,LI Yi,ZHANG Xi. The Application of Related Cytomorphological Technology in Hematological Neoplasms Research Progress[J]. China Biotechnology, 2019, 39(9): 84-90.

[14]	Chun-xiao SU,Xiao-yu ZHANG,Han ZENG,Ya-xi CHEN,Xiong-zhong RUAN,Ping YANG. Establishment and Identification of Liver-Specific CD36 Knockout Mice[J]. China Biotechnology, 2018, 38(8): 26-33.

[15]	Jing-wen XU,Xue-mei ZHANG,Zhong-xiang WU,Wen-bing ZHU,Xi JIANG,Wei GONG,Li-wei YAN,Jie SONG,Hui LI,Shao-zhong DONG. Preparation and Identification of Monoclonal Antibodies Against Tree Shrews CD3ε[J]. China Biotechnology, 2018, 38(4): 54-62.

Viewed

Full text

Abstract

Cited

Shared

Discussed